AstraZeneca's antibody drug fails in preventing COVID-19

Tuesday, 15. June 2021 08:57

AstraZeneca plc revealed on Tuesday that its monoclonal antibody drug failed to prevent symptomatic COVID-19 cases in adults who participated in the clinical trials.

The drug AZD7442 reduced the risk of developing symptoms by 33%, which is not statistically relevant according to the British company.

The treatment is similar to those developed by Regeneron Pharmaceutical and Eli Lilly & Co, which have already been authorized for mass use in the United States and the rest of the world.

Related Links: AstraZeneca plc
Breaking the News / ND